Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 457 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Ingrid Delaet sold 457 shares of the business's stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $135.00, for a total value of $61,695.00. Following the completion of the sale, the insider owned 4,730 shares in the company, valued at $638,550. This represents a 8.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX traded down $1.46 on Friday, hitting $133.46. 724,778 shares of the company's stock were exchanged, compared to its average volume of 1,143,853. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $157.98. The company has a market capitalization of $13.21 billion, a PE ratio of 45.24, a P/E/G ratio of 1.37 and a beta of 0.24. The firm's 50-day moving average is $124.19 and its 200 day moving average is $121.63.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.62). The business had revenue of $572.60 million for the quarter, compared to analysts' expectations of $587.06 million. Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. Neurocrine Biosciences's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.20 EPS. On average, analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Institutional Trading of Neurocrine Biosciences

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Neurocrine Biosciences by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company's stock valued at $1,381,331,000 after buying an additional 122,681 shares during the last quarter. Dodge & Cox boosted its stake in Neurocrine Biosciences by 83.5% in the first quarter. Dodge & Cox now owns 5,534,624 shares of the company's stock valued at $612,129,000 after acquiring an additional 2,518,199 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Neurocrine Biosciences by 44.0% during the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company's stock worth $232,037,000 after purchasing an additional 640,556 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Neurocrine Biosciences by 2.9% during the fourth quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company's stock worth $258,926,000 after purchasing an additional 53,610 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Neurocrine Biosciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company's stock worth $255,523,000 after purchasing an additional 15,830 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Canaccord Genuity Group lifted their target price on Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the company an "overweight" rating in a report on Wednesday, March 26th. The Goldman Sachs Group started coverage on shares of Neurocrine Biosciences in a research note on Thursday. They set a "buy" rating and a $182.00 target price on the stock. Guggenheim raised their price target on shares of Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Needham & Company LLC upped their price objective on Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.